ObsEva announces submission of new drug application to U.S. FDA for linzagolix for the treatment of uterine fibroids

ObsEva

15 September 2021 - NDA submission includes positive data from Phase 3 PRIMROSE trials up to 52 weeks on treatment and 24 weeks post-treatment follow-up results.

ObsEva today announced that it has submitted a new drug application to the U.S. FDA for linzagolix for the treatment of uterine fibroids.

Read ObsEva press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Medicine , US , Dossier